Videos

Featured

Broadcast

Prevention & Chronic Conditions

Heart Failure
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care

Vijay Chopra, Javed Butler, Dinesh Khullar , et al

Watch time: 1h 4m 2s

Nir Uriel

Watch time: 34m 39s (5 videos)
The Future of Heart Failure With Dr Yancy

Clyde W Yancy

Watch time: 9m 15s

Jasper J Brugts

Watch time: 2m 59s (15 videos)
AHA 25: HFpEF as an Adipose Tissue Disorder

Milton Packer

Watch time: 5m 43s
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial

Harriette Van Spall, Stephen Nicholls

Watch time: 12m 43s
AHA 25: The POLY-HF Trial

Ambarish Pandey

Watch time: 4m 15s
ESC 25 Hot Line Discussion: VICTOR: Vericiguat in Heart Failure

Harriette Van Spall, Faiez Zannad

Watch time: 13m 4s
ESC HF 25: The VELOCITY Study

Stephen J Greene

Watch time: 5m 30s
ESC 25: The REBOOT-CNIC Trial

Borja Ibanez

Watch time: 3m 53s
AHA 25: MAPLE-HCM Responder Analysis

Andrew Wang

Watch time: 3m

Broadcast

Heart Failure

Intervention
Supersaturated Oxygen Therapy (SSO2)

Gregg Stone, Robert Kloner,

Watch time: 58m 27s
Masterclass on Achievement in the Face of Adversity with Dr Eugene Braunwald

Eugene Braunwald, Harriette Van Spall

Watch time: 23m 47s
ACC 2021: Findings from the RAFT-AF Trial

Anthony SL Tang

Watch time: 15m 16s
Masterclass: Neprilysin Inhibition in Patients with reduced LVEF

Eugene Braunwald, Harriette Van Spall

Watch time: 27m 37s

Federico M Asch, Jan Belohlavek, Susheel Kodali, et al

Watch time: 4h 24m 8s (20 videos)
ACC 21: The CONNECT-HF Trial

Adam DeVore

Watch time: 7m 53s
ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod

Watch time: 15m 45s
View From the Thoraxcenter: Wrap Up of ACC 2021

Nicolas M Van Mieghem, Joost Daemen

Watch time: 33m 28s
Wearable Cardioverter Defibrillator (WCD): From Clinical Trials to Clinical Practice

Tobias Reichlin, Angelo Auricchio, Haran Burri, et al

Watch time: 1h 4m 55s
ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann

Watch time: 11m 30s
ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall

Watch time: 16m 6s

Broadcast

Vascular Disease and Surgery

Heart Failure
Baroreflex Activation Therapy for the Treatment of HFrEF

Faiez Zannad, Jörn Schmitt , Ainhoa Robles Mezcua , et al

Watch time: 1h 5m 10s

Broadcast

Heart Failure

Imaging & Diagnostics
Tips and Tricks in Imaging Your Patients With Valvular Heart Disease

Philippe Pibarot, Patrizio Lancellotti, Jose Luis Zamorano , et al

Watch time: 1h 33m 18s
EHRA 2021: Long-Term Outcome of the RACE 3 Study

Michiel Rienstra, Bao Oanh Nguyen

Watch time: 8m 29s

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Watch time: 53m 14s (5 videos)
APSC Journal Club: Landmark Trials of SGLT2 Inhibitors in HFrEF

Jack Tan Wei Chieh, Jonathan Jiunn Liang Yap, Wishnu Aditya, et al

Watch time: 1h 18m 6s